Background and Purpose— We hypothesized that a favorable vascular profile (FVP) defined as anatomic intactness of the Circle of Willis combined with a stable cerebral perfusion pressure (mean arterial blood pressure>65 mm Hg) is a prerequisite for collateral recruitment and maintenance and may improve outcome. We performed post hoc analyses of a subset of the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial data set to identify whether FVP is associated with independent outcome. Methods— SENTIS was a randomized, controlled device trial comparing hemodynamic augmentation with the NeuroFlo device to best medical treatment. We identified all patients from the primary dataset (n=515 patients) with available intracranial vascular imaging at baseline. Vascular imaging data were read blind to clinical and treatment data. We performed univariate and multivariate analyses to identify predictors of independent outcome (modified Rankin Scale 0–2) at 90 days. Results— A total of 192/515 SENTIS subjects had available baseline vascular imaging (91 treated/101 controls). Baseline characteristics did not differ between groups. Overall, FVP was seen in 89.6% of patients and predicted independent outcome in univariate (odds ratio, 7.46; 95% confidence interval, 1.68–33.18; P=0.0082) and multiple logistic regression analyses (odds ratio, 10.22; 95% confidence interval, 1.78–58.57; P=0.0091). Aside from FVP, only baseline National Institutes of Health Stroke Scales (NIHSS; odds ratio, 0.74; 95% confidence interval, 0.67–0.82, P<0.0001) entered the predictive model. There was no interaction with randomization to treatment or control. Conclusions— FVP and baseline NIHSS independently predicted outcome in this subset of the SENTIS population. FVP is a novel parameter to predict outcome of acute stroke patients and further studies will establish its potential role for selection of optimal candidates for hemodynamic augmentation. Clinical Trial Registration Information— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00119717
[1]
H. Diener,et al.
Partial Aortic Occlusion for Cerebral Perfusion Augmentation: Safety and Efficacy of NeuroFlo in Acute Ischemic Stroke Trial
,
2011,
Stroke.
[2]
Geoffrey A. Donnan,et al.
Refining the Definition of the Malignant Profile: Insights From the DEFUSE-EPITHET Pooled Data Set
,
2011,
Stroke.
[3]
K. Butcher,et al.
Safety and Feasibility of Collateral Blood Flow Augmentation After Intravenous Thrombolysis
,
2011,
Stroke.
[4]
D. Liebeskind.
Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics
,
2010,
Current opinion in neurology.
[5]
W. Heiss,et al.
Partial Occlusion of the Descending Aorta Increases Cerebral Blood Flow in a Nonstroke Porcine Model
,
2009,
Cerebrovascular Diseases.
[6]
Keith Muir,et al.
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
,
2008,
The Lancet Neurology.
[7]
D. Liebeskind.
Aortic occlusion for cerebral ischemia: From theory to practice
,
2008,
Current cardiology reports.
[8]
Scott Hamilton,et al.
Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study
,
2006,
Annals of neurology.
[9]
M. Edwards,et al.
Trial
,
2004,
The Lancet.
[10]
Cornelius Weiller,et al.
Prediction of Malignant Middle Cerebral Artery Infarction by Early Perfusion- and Diffusion-Weighted Magnetic Resonance Imaging
,
2003,
Stroke.